Foresee Pharmaceuticals Co., Ltd. is a Taiwan-based company mainly engaged in the research and development of new pharmaceuticals. The Company's main products include prostate cancer treatment product FP-001 and asthmatic/chronic obstructive pulmonary disease treatment product FP-025. It also engages in new pharmaceuticals clinic trial business.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
28/07/26	NT$80.70	-1.10%	135,612
27/07/26	NT$81.60	-0.49%	86,588
24/07/26	NT$82.00	-1.20%	71,048
23/07/26	NT$83.00	0.00%	81,183
22/07/26	NT$83.00	+0.97%	165,207

End-of-day quote Taipei Exchange

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

80.70TWD

Average target price

153.00TWD

Spread / Average Target

+89.59%

Consensus

Quarterly revenue - Rate of surprise

Company calendar

End-of-day quote Taipei Exchange Other stock markets 28/07/2026			5-day change	1st Jan Change
80.70 ^TWD	-1.10%		+1.25%	+0.12%

07-09	Foresee Pharmaceuticals Co., Ltd. Announces Appointment of Brian J. Groch to Chief Commercial Officer, Effective July 1, 2026	CI
06-08	Foresee Pharmaceuticals Oral ALDH2 Activator Mirivadelgat Enters Clinical Testing in Parkinson's Disease in the SLEIPNIR Phase 2A Platform Trial	CI

Market Cap	12.71B 393M 345M 321M 295M 553M 37.52B 563M 3.81B 1.49B 18.61B 1.47B 1.44B 64.28B	P/E 2024	-9.84x	P/E 2025	-14.1x
Enterprise Value	12.47B 385M 338M 315M 289M 543M 36.79B 552M 3.73B 1.46B 18.24B 1.45B 1.41B 63.03B	EV / Sales 2024	26x	EV / Sales 2025	28.9x
Free-Float	47.69%	Yield 2024 *	-	Yield 2025	-

07-09	Foresee Pharmaceuticals Co., Ltd. Announces Appointment of Brian J. Groch to Chief Commercial Officer, Effective July 1, 2026	CI
06-08	Foresee Pharmaceuticals Oral ALDH2 Activator Mirivadelgat Enters Clinical Testing in Parkinson's Disease in the SLEIPNIR Phase 2A Platform Trial	CI
05-27	Foresee Pharmaceuticals Completes Casppian Phase 3 Study and Confirms Topline Results for FP-001 42 Mg in Central Precocious Puberty	CI
05-14	Foresee Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-13	Foresee Pharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-06	Foresee Pharmaceuticals Announces Positive ChHMP Opinion Recommending Approval Of CAMCEVI 21 Mg 3-Month Strength In European Union	CI
02-04	Foresee Pharmaceuticals Co., Ltd. Receives the Fourth Positive Recommendation from the DSMB to Continue the Casppian Ph3 Study, for Central Precocious Puberty	CI
12-24	Foresee Pharmaceuticals Announces Casppian Phase 3 Study Meets Primary Efficacy Endpoint, Demonstrating Robust Lh Suppression with 6-Month Dosing Interval of Leuprolide Mesylate	CI
11-13	Foresee Pharmaceuticals Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
29/08/25	Foresee Pharmaceuticals Announces FDA Approval of CAMCEVI ETM for the Treatment of Advanced Prostate Cancer	CI
12/08/25	Foresee Pharmaceuticals Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
31/07/25	Foresee Pharmaceuticals Co., Ltd. announced that it expects to receive TWD 400 million in funding	CI
17/06/25	Foresee Completes Phase 3 CASPPIAN Trial Enrollment For Central Precocious Puberty	RE

12/08/24	Foresee Pharmaceuticals Announces Several New Developments Related to its SIF Long-Acting Injectable (LAI) Technologies - Solidifying its Position as a Leader in Complex Long-Acting Injectable Products	AQ
02/04/24	Foresee Pharmaceuticals Receives Positive Recommendation from DSMB to Continue the Casppian Study, a Phase 3 Clinical Trial of Leuprolide Injectable Emulsion for the Treatment of CPP	AQ
31/10/23	Foresee Pharmaceuticals to Present at the American Heart Association Annual Meeting Focusing on its ALDH2 activator FP-045 in Pulmonary Hypertension Associated with Interstitial Lung Disease	AQ
02/10/23	Foresee Pharmaceuticals to Present Phase 1/2 Fanconi Anemia Clinical Study Design for its ALDH2 activator FP-045 at the Fanconi Anemia Research Fund 2023 Scientific Symposium	AQ
02/10/23	Foresee Pharmaceuticals Announces Publication of Preclinical Data in Nature Communications	AQ

Foresee Pharmaceuticals Co., Ltd. Stock

Stocks

6576

TW0006576002

Biotechnology & Medical Research

Valuation: Foresee Pharmaceuticals Co., Ltd.

Chart: Foresee Pharmaceuticals Co., Ltd.

Latest news : Foresee Pharmaceuticals Co., Ltd.

Press Releases: Foresee Pharmaceuticals Co., Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: Foresee Pharmaceuticals Co., Ltd.

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

1 day	-1.10%
1 week	+1.25%
Current month	-0.12%
1 month	+3.46%
3 months	-0.98%
6 months	-2.54%
Current year	+0.12%

1 week	79.5	83.3
1 month	78.9	86.6
Current year	75.1	88.3
1 year	71.9	93.7
3 years	57.7	107.5
5 years	57.7	141
10 years	35.1	141

Manager	Title	Age	Since
Benjamin Chien CEO	Chief Executive Officer	-	08/02/2013
Yu Hua Li CTO	Chief Tech/Sci/R&D Officer	-	09/07/2015
Max Chan DFI	Director of Finance/CFO	58	07/10/2019

Director	Title	Age	Since
Chang Jen Yan BRD	Director/Board Member	-	10/01/2013
Sheng Lee Yi BRD	Director/Board Member	-	10/01/2013
George Lee BRD	Director/Board Member	75	03/08/2015

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
FORESEE PHARMACEUTICALS CO., LTD.	-1.10%	+1.25%	+9.80%	-3.24%	398M
LONZA GROUP AG	+0.14%	-0.67%	-0.88%	+11.02%	47.74B
REVOLUTION MEDICINES, INC.	-3.36%	-0.81%	+387.95%	+607.16%	39.98B
BEONE MEDICINES AG	+0.60%	+2.82%	+11.26%	+45.55%	36.23B
IQVIA HOLDINGS INC.	+11.22%	+17.59%	+19.89%	+4.84%	35.59B
CELLTRION, INC.	-0.73%	+2.78%	+4.65%	+41.16%	27.91B
ASCENDIS PHARMA A/S	-1.82%	-2.74%	-	-	16.71B
MEDPACE HOLDINGS, INC.	-2.39%	+8.43%	+27.25%	+126.24%	16.45B
EUROFINS SCIENTIFIC SE	+2.39%	-1.64%	+4.74%	+9.95%	13.21B
ICON PUBLIC LIMITED COMPANY	+6.87%	+8.06%	-5.07%	-28.59%	12.93B
Average	+1.22%	+2.23%	+51.06%	+90.45%	24.72B
Weighted average by Cap.	+1.38%	+2.95%	+74.48%	+128.49%

	2024	2025
Net sales	419M 12.93M 11.35M 10.57M 9.72M 18.22M 1.24B 18.53M 125M 49.08M 613M 48.55M 47.5M 2.12B	431M 13.32M 11.69M 10.89M 10.01M 18.77M 1.27B 19.09M 129M 50.55M 631M 50.01M 48.93M 2.18B
Net income	-1.08B -33.39M -29.3M -27.29M -25.1M -47.05M -3.19B -47.86M -324M -127M -1.58B -125M -123M -5.47B	-883M -27.28M -23.94M -22.29M -20.5M -38.44M -2.61B -39.1M -264M -104M -1.29B -102M -100M -4.47B
Net Debt	-1.11B -34.19M -30.01M -27.94M -25.7M -48.18M -3.27B -49M -332M -130M -1.62B -128M -126M -5.6B	-248M -7.65M -6.72M -6.25M -5.75M -10.78M -731M -10.97M -74.2M -29.04M -363M -28.73M -28.11M -1.25B